Outside the Guidelines: Denosumab Overuse in Prostate Cancer
Kort samengevat
Many men with castration-sensitive prostate cancer receive the bone-modifying agent to prevent skeletal-related events, but that practice is not recommended and costs Medicare millions annually.
Verder lezen bij de bron
Bekijk het volledige nieuwsbericht rechtstreeks bij Medscape.
Lees het volledige bericht ↗